FDA Approves New U.S. Labeling for ISENTRESS to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has approved new labeling for ISENTRESS Film-coated ... (more)
http://www.pmpnews.com/news/fda-approves-new-us-labeling-isentress%C2%AE-raltegravir-include-240-week-results-startmrk-study-ise
http://www.pmpnews.com/news/fda-approves-new-us-labeling-isentress%C2%AE-raltegravir-include-240-week-results-startmrk-study-ise
